Investor Presentaiton

Performance: 2023 full year outlook considerations to support modelling Specialty Medicines turnover Increase mid to high single-digit % for Specialty Medicines, excluding Xevudy sales HIV to increase mid single-digit % Oncology to decrease mid-teens %, before returning to growth in 2024 Turnover to adj. operating profit items COGS: to increase at a rate slightly below turnover SG&A: to increase at a rate broadly aligned to turnover R&D: to increase at a rate slightly below turnover Royalties: around £800m GSK adj. operating profit is expected to increase between 10% and 12% The above items exclude the impact of COVID-19 solutions Vaccines turnover Increase mid-teens %, excluding pandemic adjuvant sales Shingrix to deliver another record year for sales with double-digit % growth Flu to decrease low single-digit % Meningitis to increase mid-teens % Established Vaccines to increase low single-digit % Adj. operating profit to adj. EPS items Interest: between £750m to £800m Share of associates: negligible Tax rate: around 15% Non-controlling interest: ViiV is main ongoing NCI, with Q1 2022 'Other' NCI not repeating GSK adj. EPS is expected to increase between 12% and 15% General Medicines turnover Slight decrease COVID-19 solutions Not anticipating significant sales Expect this to reduce GSK turnover growth by approximately 9% and reduce adj. operating profit growth by 6% to 7% Dividend Expect 56.5p per share All turnover and growth comments at CER. Adj. is abbreviation for Adjusted. All expectations and targets regarding future performance and the dividend should be read together with the "Guidance, assumptions and cautionary statements" on pages 68 to 69 of our fourth quarter 2022 earnings release, page 2 of our fourth quarter earnings release and the cautionary statement slide included with this presentation. Tax rate expectation is based on enacted legislation and is reflective of the anticipated performance of the business and key assets. The tax rate could fluctuate in individual years due to the timings of settlements of open years with tax authorities, as we continuously bring our tax affairs up to date. Interest expectation assumes no significant adverse movements in interest rates. GSK 34

View entire presentation